Updated Guidance on Hormone Therapy in Menopause

July 17, 2017

From NEJM Journal Watch(July 11, 2017): "North American Menopause Society Updates Its Position Statement on Hormone Therapy: 2017. Reaffirmation of HT's efficacy for managing vasomotor symptoms and genitourinary syndrome of menopause...Moderate to severe vasomotor symptoms (VMS) affect a high percentage of peri- and postmenopausal women. VMS may persist for many years, negatively affecting quality of life. Genitourinary syndrome of menopause (GSM) is also highly prevalent and may become more bothersome as women age. Using an evidence-based approach, an advisory panel of >20 experts updated the hormone therapy (HT) guidelines of the NAMS." Read more.

*Source: NEJM Journal Watch

Learn more about menopause.

*The views expressed in this article are those of the source and do not necessarily reflect the views of Lab Tests Online or the Lab Tests Online Editorial Review Board.